Abstract
NUP98 fusions are molecularly rare in T-cell acute lymphoblastic leukemia (T-ALL), with limited data available regarding treatment response and clinical outcomes. Here, we report a case of T-ALL harboring a NUP98::ADD3 fusion (involving NUP98 exon 13 and ADD3 exon 13), representing only the second documented instance of this genetic rearrangement in T-ALL. Notably, the patient demonstrated refractoriness to venetoclax-based chemotherapy. To our knowledge, this is the first report of a T-ALL case with the NUP98::ADD3 fusion exhibiting resistance to venetoclax-containing regimens.